Savara Inc. Form 8-K Summary
Business Context and Reporting Period
Savara Inc. (SVRA), a Delaware corporation, filed this Current Report on Form 8-K on March 26, 2025. The filing details the entry into a new material definitive loan agreement and the termination of a prior loan agreement with Silicon Valley Bank.
Key Financial Metrics and Debt Structure
The filing focuses on debt financing rather than operational financial results. Key metrics include:
- Total Facility Size: Up to $200 million in term loans.
- Initial Draw: $30 million advanced on March 26, 2025.
- Use of Proceeds: Repayment of prior Silicon Valley Bank obligations, transaction expenses, and general corporate purposes.
- Interest Rate: Floating rate equal to the greater of the Prime Rate or 6.0%, plus 1.45% (reducing to 1.20% upon achieving specific revenue milestones).
- Maturity Date: April 1, 2030.
- Repayment Terms: Interest-only monthly payments through March 2028, followed by principal and interest installments. If the FDA Approval Milestone is met, the interest-only period extends to maturity.
Material Changes and Milestones
The Company terminated its Amended and Restated Loan and Security Agreement with Silicon Valley Bank dated April 21, 2022, in full satisfaction of obligations. The new facility includes conditional tranches based on specific milestones:
- Approval Milestone: Subject to FDA approval of MOLBREEVI for aPAP, the Company may draw up to $40 million by March 15, 2026, and another $40 million by December 15, 2026.
- Revenue Milestone: Subject to achieving trailing six-month net product revenue of at least 75% of an agreed plan (post-March 31, 2027), the Company may draw up to $20 million by December 31, 2027.
- Discretionary Tranche: Up to $70 million subject to Lenders' investment committee approval.
Covenants, Risks, and Management Commentary
The Loan Agreement includes significant covenants and liquidity requirements:
- Cash Requirement: Beginning April 1, 2026, the Company must maintain unrestricted cash equal to 50% of the outstanding principal. This increases to 70% if the Approval Milestone is not achieved, or decreases to 35% upon achieving the Revenue Milestone. This requirement is waived if market capitalization exceeds $600 million.
- Conditional Minimum Revenue Covenant: If more than $50 million is drawn, the Company must maintain trailing six-month net product revenue of at least 65% of a sales forecast or $100 million (whichever is applicable), starting nine months after the Approval Milestone. This covenant is waived if market cap exceeds $500 million and the 50% cash requirement is met.
- Collateral: The loan is secured by a first-priority security interest in all tangible and intangible assets, excluding intellectual property (which is subject to a negative pledge).
- Risk Factors: Failure to meet FDA approval or revenue targets could restrict access to additional funding tranches and increase cash reserve requirements.
Investor Verification Checklist
- Verify the status of the FDA application for MOLBREEVI for the treatment of aPAP to assess the likelihood of the $80 million Approval Milestone tranches.
- Review the Company's current cash position to ensure compliance with the 50% (or 70%) cash reserve requirement starting April 1, 2026.
- Monitor the Company's market capitalization relative to the $500 million and $600 million thresholds that waive specific covenants.
- Confirm the specific "agreed upon revenue plan" referenced in the Revenue Milestone, as this is not detailed in the 8-K.
- Check for the filing of the full Loan Agreement text in the upcoming Form 10-Q for the period ended March 31, 2025.